Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Trygg Pharma Buys U.K. Factory
by Alex Scott
July 23, 2012
| A version of this story appeared in
Volume 90, Issue 30
Trygg Pharma, a Norwegian producer of omega-3 concentrates for food and pharmaceutical applications, has acquired a facility in Seal Sands, England, from the drugmaker Lundbeck for $20 million. The facility has been mothballed since Lundbeck switched production to other European sites three years ago. Trygg says it plans to restart the plant to produce omega-3 from fish oil. Oslo-based Aker BioMarine and Lindsay Goldberg, a New York City-based private equity firm, jointly own Trygg.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X